Celldex Therapeutics Inc.
CLDX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.09B
Close$
$0.05
99.8% downside
Current Fair Value
99.8% downsideOvervalued by 99.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.09 Billion |
|---|---|
| Enterprise Value | $2.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.9 |
| Beta | 0.98 |
| Outstanding Shares | 66,566,000 |
Return
| Return on Equity | -62.18% |
|---|---|
| Return on Assets | -55.49% |
| Return on Invested Capital | -46.17% |
Valuation & Multiples
| P/E Ratio | -7.37 |
|---|---|
| PEG | -15.94 |
| Price to Sales | - |
| Price to Book Ratio | 4.96 |
| Enterprise Value to Revenue | 2509.13 |
| Enterprise Value to EBIT | -9.69 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.13
Average shareholder expectationRevenue Estimate
$795,364
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-1.08
Average shareholder expectationRevenue Estimate
$802,636
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.9262▲ 144.70% |
|---|---|
| Total Calls | 98,900▲ 71.70% |
| Total Puts | 190,500▲ 590.22% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 109.69%▼ 0.82% |
|---|---|
| Total Invested | $2.31B▲ 16.01% |
| Investors Holding | 233▲ 46.00% |
ESG Score
No data
About Celldex Therapeutics Inc.
CEO: Anthony Marucci Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeu...